# AEGIS Misdiagnosis Review 001

Objective: attempt to invalidate the major conclusions produced tonight.

Scope: existing Research Journal and AEGIS diagnostic review evidence only. This review adds no architecture, schemas, systems, runtime truth changes, trading logic, trade advice, candidates, or allocation authority.

Review stance: assume each conclusion is wrong until existing evidence makes that assumption difficult to maintain.

Inputs:
- `journal_review_001.md`
- `journal_review_002.md`
- `root_cause_review_001.md`
- `outcome_maturity_acceleration_review_001.md`
- `evidence_accumulation_forecast_review_001.md`
- `c2_trend_eq_outcome_review_001.md`
- `open_paper_position_outcome_follow_through_review_001.md`

## 1. Outcome Maturity Is The Primary Bottleneck

Strongest supporting evidence:

- On 2026-06-03, AEGIS had 63 paper positions, 51 open positions, 12 closed positions, and 12 included validation samples.
- Research quality showed 10 hypotheses, 6 underpowered, 4 blocked, and 0 ready for capital review.
- Statistical sufficiency showed 9 hypotheses, 8 underpowered, 1 validation-ready, and 0 validated.
- Sleeve evidence certification showed 5 evaluated sleeves, all UNDERPOWERED, with 1 BUILDING_SAMPLE and 4 ZERO_SAMPLE.
- Open-position follow-through found all 51 reviewed open positions remained `HOLD`; 47 of 51 had no near-term deterministic closure proximity.

Strongest contradictory evidence:

- Candidate conversion is also severe: 42 raw signals produced 1 generated candidate and 1 paper position on 2026-06-03.
- Several hypotheses remain blocked before outcome testing because of no candidate flow, no observation flow, no paper path, implementation gaps, or data-source issues.
- The evidence forecast says additional useful samples are not assured; near-term yield may be only 0 to 2 Trend EQ samples under existing deterministic rules.
- The 2026-06-04 sequence showed data or authority blockers can interrupt interpretation even when prior-day outcome artifacts exist.

Alternative explanation:

Outcome maturity may be the most visible bottleneck because it is downstream. The deeper bottleneck could be candidate-to-paper conversion and measurable-flow generation. If too few hypotheses can reach paper observation flow, waiting for outcomes will not repair the system.

Confidence level: HIGH, with an upstream-cause caveat.

What evidence would falsify it:

- A review showing that closed, distributed validation samples are now sufficient but AEGIS remains blocked primarily by candidate conversion, data authority, paper-path defects, or governance interpretation.
- Multiple hypotheses reaching sufficient closed samples while still producing no reusable research learning because upstream candidate and paper-path quality are defective.
- Evidence that the existing open-position population cannot materially increase validation maturity under deterministic closure rules, making candidate or paper-path creation the true binding constraint.

## 2. Candidate Volume Is A Poor Proxy For Quality

Strongest supporting evidence:

- Candidate diagnostics showed 42 raw signals but only 1 generated candidate and 1 valid candidate contract.
- Detailed candidate diagnostics split most rejected rows into expected portfolio-gate suppressions rather than direct quality failures.
- `HYP_EVENT_DISLOCATION_REPRICING_V1` had 23 candidates but 0 paper positions and 0 usable validation samples.
- Sleeve evidence certification classified all evaluated sleeves as UNDERPOWERED despite candidate and paper-trade inventories.

Strongest contradictory evidence:

- `C2_TREND_EQ_PRIMARY_V1` had the highest candidate and paper-position inventory and is also the only meaningful closed-sample evidence source.
- More candidate and paper-position volume appears necessary for outcome accumulation, even if it is not sufficient for quality.
- Low-volume sleeves have not yet generated enough closed samples to disprove a practical relationship between volume and learning yield.

Alternative explanation:

Candidate volume may be a weak standalone quality proxy but a useful stage-specific throughput signal. It should not be discarded; it should be interpreted only after governance, certification, paper-position conversion, and closed-outcome evidence are separated.

Confidence level: HIGH.

What evidence would falsify it:

- A cross-sleeve review showing that higher candidate volume consistently predicts valid candidate contracts, paper positions, closed validation samples, and positive evidence after controlling for governance suppression and certification state.
- Evidence that low-volume sleeves repeatedly underperform in outcome maturity and evidence quality while high-volume sleeves repeatedly improve validation quality.

## 3. Low Candidate Production Is Not Primarily Sleeve Weakness

Strongest supporting evidence:

- Sleeve throughput diagnostics showed 5 flowing sleeves, 4 dormant sleeves, 1 blocked sleeve, and 0 underproducing sleeves.
- Sleeve throughput scorecard classified 5 sleeves as FLOWING, 4 as HEALTHY_NO_CANDIDATE, 1 as NEEDS_DATA, and 0 as NEEDS_REPAIR or NEEDS_GOVERNANCE.
- Dormant-sleeve diagnostics identified valid no-signal conditions, thresholds not met, optional simulator filtering, and one data/runtime blocker rather than broad sleeve failure.
- Journal Review 001 and OBS_0014 concluded that low production should not be labeled sleeve weakness until no-signal, threshold, data, governance, certification, and outcome-maturity diagnostics are separated.

Strongest contradictory evidence:

- Some hypotheses have no candidate flow, no observation flow, no paper path, implementation incomplete status, or REDESIGN classifications.
- `C2_EVENT_DISLOCATION_V1` exposed a producer-runtime/data path issue, not just healthy selectivity.
- Four evaluated sleeves had paper activity but 0 closed samples, which could reflect weak sleeve design, unsuitable closure logic, or insufficient paper-position depth.
- The evidence base is too immature to prove that non-producing sleeves are high quality.

Alternative explanation:

Low candidate production may be a mixed condition: some sleeves are behaving correctly under no-signal or threshold rules, while others may have implementation, data, paper-path, or design weaknesses that are not yet measured as sleeve-quality failures.

Confidence level: MEDIUM.

What evidence would falsify it:

- Repeated review cycles showing HEALTHY_NO_CANDIDATE sleeves fail to produce candidates during favorable, threshold-satisfying market conditions.
- Evidence that no-signal or threshold explanations are masking defective trigger definitions.
- Repair of data and paper-path blockers followed by continued failure to produce candidates or usable outcomes.
- Closed-outcome evidence showing non-producing or low-producing sleeves consistently generate weak results when they eventually become measurable.

## 4. Research Attention Allocation Is More Useful Than Capital Allocation

Strongest supporting evidence:

- Research quality, hypothesis decision policy, and research allocation recommendation artifacts showed 0 ready for capital review.
- Capital authority readiness kept capital allocation and broker execution disallowed.
- Research attention artifacts still produced differentiated read-only decisions: hold, pause, decrease, redesign, needs-data, investigate-more, and research-attention-only program decisions.
- Outcome evidence remained underpowered, concentrated, and early; no hypothesis was validated.

Strongest contradictory evidence:

- The term allocation can obscure the distinction between research attention allocation and capital allocation.
- Research capital allocation artifacts already produced research-program decisions, which may look capital-adjacent even though they were explicitly research-attention-only.
- `HYP_LARGE_CAP_EQUITY_MOMENTUM_20_60D_V1` reached validation-ready state at the statistical-sufficiency layer, showing that some capital-review-adjacent triage can occur before final validation.

Alternative explanation:

The correct conclusion may be narrower: research triage and evidence-follow-through are useful now; capital allocation is not. The system should avoid letting capital-language artifacts create the impression of investable readiness.

Confidence level: HIGH for real capital allocation; MEDIUM-HIGH for terminology clarity.

What evidence would falsify it:

- One or more hypotheses or sleeves emitted as READY_FOR_CAPITAL_REVIEW or CAPITAL_REVIEW by existing artifacts with sufficient, positive, distributed, closed-outcome evidence.
- Evidence that capital-review-style analysis improves research quality without implying trade sizing, execution, or capital authority.
- A runtime truth change making capital allocation allowed through existing policy and evidence gates, paired with mature validation evidence.

## 5. Technical Indicator Claims Are Weak

Strongest supporting evidence:

- Technical Strategy Factory reviews found broad or standalone technical claims unsupported, false-positive-prone, baseline-recoverable, or non-generalizing.
- Evidence Test v2 had 62 blocked evidence items and 0 supported evidence items.
- Out-of-fixture non-naive rebenchmark found 0 qualified research asset candidates and 0 unique supported evidence count.
- Journal Review 001 refined the conclusion: technical evidence must be relationship-specific and split by evidence type.

Strongest contradictory evidence:

- Some real-data technical patterns and controlled fixture candidates existed.
- Repaired-feature and non-naive tests improved question productivity and produced in-fixture support.
- `C2_TREND_EQ_PRIMARY_V1` is a technical or momentum-adjacent sleeve and is the only meaningful closed-sample evidence stream, even though early results are weak.
- Context-linked or mechanism-specific technical structures have not been fully disproven.

Alternative explanation:

Standalone indicator claims are weak, but technical structure is not categorically invalid. The failure may be in broad indicator framing, fixture dependence, and lack of relationship-specific validation rather than in all technical evidence.

Confidence level: MEDIUM-HIGH for standalone claims; MEDIUM for technical evidence as a whole.

What evidence would falsify it:

- Out-of-fixture, baseline-adjusted, relationship-specific technical tests producing durable support.
- Closed-outcome evidence showing technical structures improve discovery quality, validation samples, or benchmark-relative results without hindsight or fixture dependence.
- Evidence that technical claims remain supported after false-positive, baseline, regime, and sample-independence controls.

## 6. C2_TREND_EQ_PRIMARY_V1 Is The Primary Evidence Source

Strongest supporting evidence:

- `C2_TREND_EQ_PRIMARY_V1` had 53 paper trades, 41 open positions, 12 closed positions, and all 12 usable validation samples in the 2026-06-03 evidence.
- It was the only sleeve with meaningful closed-sample flow, deterministic exits already firing, data quality PASS, and no missing authorities on the pinned day.
- Associated hypothesis evidence showed 53 paper positions, 12 usable validation samples, and VALIDATION_READY state.
- Other evaluated sleeves remained ZERO_SAMPLE with 0 closed positions.

Strongest contradictory evidence:

- Its primary-source status is based on measurability and sample count, not positive quality.
- Early realized evidence was weak: negative realized PnL, negative expected value, low win rate, and profit factor below 1.
- All other sleeves being ZERO_SAMPLE means the comparison set is immature, not necessarily inferior.
- Open-position follow-through found only 2 Trend EQ positions near stop-loss and no Trend EQ positions near take-profit or max-hold thresholds, so near-term deepening may be limited.

Alternative explanation:

`C2_TREND_EQ_PRIMARY_V1` is the primary current evidence source because it is the only functioning closed-sample path at scale. It should not be treated as the best hypothesis, representative of all AEGIS discovery, or evidence that technical/momentum logic is validated.

Confidence level: HIGH for primary current source by sample count; LOW for any implication of proven quality.

What evidence would falsify it:

- Another sleeve producing comparable or superior closed, included validation samples.
- Trend EQ artifacts becoming stale, blocked, or excluded from graph-visible evidence.
- Trend EQ samples failing quality filters while another sleeve accumulates valid, independent, positive evidence.
- A review showing that Trend EQ sample concentration is a historical artifact no longer relevant to current evidence accumulation.

## Cross-Conclusion Contradictions

The strongest contradiction across the review is that outcome maturity may be a downstream symptom rather than the deepest cause. Existing evidence supports outcome maturity as the primary visible bottleneck, but candidate conversion, paper-path depth, and data authority determine whether enough hypotheses can ever reach outcome maturity.

The second strongest contradiction is that `C2_TREND_EQ_PRIMARY_V1` dominates the evidence surface while also showing weak early realized performance. This makes AEGIS vulnerable to overlearning from the only measurable stream.

The third strongest contradiction is that low candidate production is not currently proven to be sleeve weakness, but the evidence is not strong enough to prove sleeve quality either. Healthy no-signal classifications are useful, not final.

## Most Likely Place AEGIS Is Still Fooling Itself

AEGIS is most likely still fooling itself by treating the only working evidence path as representative of the whole research system.

`C2_TREND_EQ_PRIMARY_V1` is the primary evidence source because it has paper-position depth, deterministic exits, and closed samples. That does not mean it is high quality, broadly representative, or sufficient to validate AEGIS discovery. The same evidence that makes it useful for learning also shows weak early realized performance and heavy concentration.

The most dangerous misdiagnosis would be to say: outcome maturity is the bottleneck, therefore wait for existing positions and the system will mature. The hostile interpretation is narrower: outcome maturity is the current blocking surface, but the system may also need better candidate-to-paper conversion, more distributed paper-position depth, and cleaner evidence authority before additional outcomes become useful.

## Overall Judgment

Most robust conclusion: research attention allocation is more useful than capital allocation while all reviewed capital-readiness surfaces show 0 eligible rows.

Most fragile conclusion: low candidate production is not primarily sleeve weakness. The current evidence rejects a broad weak-sleeve diagnosis, but it has not proven that all low-production sleeves are healthy.

Strongest contradiction found: outcome maturity may be downstream of candidate conversion and paper-path availability. More closed outcomes are necessary, but not sufficient, if most sleeves cannot reach measurable evidence flow.
